Sativex regulatory update

GW Pharmaceuticals said Swissmedic approved Sativex to treat moderate to severe spasticity in multiple sclerosis (MS) patients who have not responded adequately to other anti-spasticity medications. GW said marketing partner Almirall S.A. (Madrid:ALM, Barcelona, Spain) will launch the product after pricing and reimbursement negotiations in Switzerland are complete. Sativex is approved in 23 countries, including Canada, Spain, New Zealand, Denmark and the U.K. In May 2012, the product was recommended for approval under the EU Mutual Recognition Procedure (see BioCentury, May 14, 2012 & July 29, 2013). ...